On April 4, 2022 VerImmune, Inc. ("VerImmune"), a biotechnology company developing new therapeutic modalities that redirects the body’s pre-existing immunity toward cancer, reported that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,285,203 entitled "Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses (Press release, VerImmune, APR 4, 2022, View Source [SID1234611392])." This patent protects VerImmune’s technology platform including critical compositions-of-matter and their use in treating cancer. The patent is also expected to provide protection until at least 2037, without accounting for potential Patent Term Extension (PTE).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The award of this issued composition of matter patent in the United States with a significant lifespan is an important corporate milestone for our growing company and marks the maturing of our robust intellectual property estate," said Joshua Wang, Founding CEO of VerImmune.

VerImmune’s technology platform, discovered internally and wholly owned by VerImmune, provides unique products that harness the body’s pre-existing T-cell memory against pathogens and specifically redirects these responses to attack cancer. This is a potentially broadly applicable treatment paradigm, based on a single therapy, that can act against multiple human cancers due to the ubiquitous nature of pre-existing responses to childhood vaccines and/or past infections.

On April 4, 2022 Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the "Company") reported that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of 3,878,789 common shares at a purchase price of $1.65 per share, sold pursuant to a registered direct offering (Press release, Nymox, APR 4, 2022, View Source [SID1234611391]). The Company has also issued to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 3,878,789 common shares. The warrants have an exercise price of $2.00 per share and will expire 5 years from the date of an effective registration statement covering the shares underlying the warrants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nymox is also pleased to report that the offering has the strong support of long-term shareholders and would like to thank one of our Directors, James G. Robinson for his participation in the offering, consisting of 1,151,515 units ($1.9 million).

Nymox intends to use the proceeds for general corporate purposes, including working capital. The total amount raised was increased from $5 million as announced in the earlier press release of March 18, 2022.

A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

This offering of the common shares (but not the warrants or the common shares underlying the warrants) was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-261571) previously filed with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of the proposed offering was filed with the SEC and is available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected]. Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Nymox has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Nymox and such offering.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the common shares underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying common shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT) was submitted in a New Drug Application (NDA) to the FDA on March 3, 2022. The Company will soon be submitting applications in other major jurisdictions, including Europe.

On April 4, 2022 RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with malignant pleural effusion and mesothelioma, reported the dosing of the first patient with RSO-021 as part of its first-in-human Phase 1/2 clinical trial (MITOPE) at the University Hospitals of Leicester in the U.K (Press release, RS Oncology, APR 4, 2022, View Source [SID1234611390]). RSO will be evaluating its novel treatment, RSO-021, against a specific mitochondrial enzyme regulating oxidative stress pathways in cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This novel therapeutic approach has proven in pre-clinical studies to significantly reduce tumor burden in malignant mesothelioma and other cancer types by irreversibly binding and inhibiting a key enzyme in the antioxidant signaling network within the mitochondria of malignant cells.

"Our team is excited to begin patient dosing with our novel metabolic therapy. This is a significant milestone in developing a treatment for people suffering from this horrible disease," stated CEO Jarrett Duncan. "We are eager to see activity of our drug in humans following our successful pre-clinical studies in multiple indications," added COO and Head of Business Development, George Naumov, Ph.D.

"Mesothelioma remains a lethal cancer lacking effective treatments, particularly in patients with relapsed disease. This exciting study of a first in class PRX3 inhibitor is hoped to show promising signals that could lead to development of a new approach to tackle this cancer." said the clinical investigator from Leicester Hospital, Professor Dean Fennell, FRCP FRSB.

About MITOPE clinical trial

The MITOPE Phase 1/2 clinical trial is a first-in-human study that will evaluate RSO-021 as a treatment for patients suffering from MPE and mesothelioma. RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. The MITOPE trial is planned to open in six UK-based clinical institutions and will be recruiting patients in collaboration with Mesothelioma UK. For more MITOPE information review View Source or contact [email protected]. The study is supported by NIHR.

On April 4, 2022 Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, reported an increase of 53% year-over-year preliminary unaudited gross ZTlido sales in March. ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021 (Press release, Sorrento Therapeutics, APR 4, 2022, View Source [SID1234611389]). In 1Q2022, the preliminary unaudited gross sales for ZTlido are approximately $18.4 million, compared to $14.6 million in 1Q2021, representing a growth of 26% .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased with the progress we have made to ensure patient and physician awareness, access, and adoption to ZTlido. Strong year-over-year sales growth continues to be driven by the expanding payor coverage for ZTlido as a cornerstone of topical lidocaine treatment in neuropathic pain related to post-herpetic neuralgia (PHN) where it continues to be used as first-line therapy," said Jaisim Shah, Chief Executive Officer of Scilex. "Importantly, our diversified portfolio of unique, best-in-class programs will increasingly allow us to offer complementary and standalone opioid-sparing outpatient pain management solutions."

The Scilex commercial team has demonstrated success in expanding access and currently has prioritized and targeted select payor accounts representing approximately 200 million of over 300 million covered lives in the US.

Scilex Holding Company and Vickers Vantage Corp. I (Nasdaq: VCKA) ("VCKA"), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, entered into a definitive business combination agreement ("BCA") on March 17, 2022. Upon the closing of the transaction, the combined company (the "Combined Company") will be renamed Scilex Holding Company, and its common stock is expected to be listed on Nasdaq under the ticker symbol "SCLX". The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the third quarter of 2022, is subject to the approval of VCKA’s shareholders and the satisfaction or waiver of certain other customary closing conditions.

On April 4, 2022 Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, reported that it has entered a €1.5 million Loan Agreement with the regional Bpifrance in Strasbourg (Grand Est Bpifrance), via Priothera SAS, its French affiliate (Press release, Priothera, APR 4, 2022, View Source [SID1234611386]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This R&D innovation loan will be used to further support the clinical manufacture of mocravimod for a European, US and Asian registration-enabling clinical trial with mocravimod in Acute Myeloid Leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT).

Brice Suire, Co-Founder and Chief Financial Officer of Priothera, said: "This non-dilutive financing, alongside the funding from the European Investment Bank that we announced recently, will play an important role in financing the development of mocravimod. It will allow us to strengthen our local French team and accelerate delivery of the clinical supply of mocravimod needed for our upcoming registration-enabling global clinical trial. We are very pleased with the confidence shown by Grand Est Bpifrance in supporting the Company in its development program."

Alban Stamm, Innovation Manager at Bpifrance Alsace commented: "We believe that Priothera, with its drug candidate mocravimod, has the potential to enable a major breakthrough in preventing transplant rejection which would provide a tremendous benefit to AML patients undergoing a stem cell transplant. The Bpifrance loan will support Priothera’s key objective of establishing human proof of concept and generating registrational data, allowing the company to create significant socio-economic value in France and beyond that for patients globally."

Mocravimod, a sphingosine 1 phosphate (S1P) receptor modulator which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of HSCT in patients with AML. Moreover, it has shown clinically relevant benefits in an early clinical study in patients with hematologic malignancies undergoing HSCT.